

양극성 장애 환자에서 Apo-1/Fas Promoter 유전자 다형성*

김규현** · 손소정*** · 이희제** · 김종우** · 정주호**†

Association of a Polymorphism in the Promoter Region of Apo-1/Fas Gene with Bipolar Disorder*

Kyu Hyun Kim, M.D., ** So-Jeong Son, M.D., *** Hee Jae Lee, M.D., **
Jong Woo Kim, M.D., ** Joo-Ho Chung M.D., **†

ABSTRACT

Objective : Recently, many experimental evidences have been reported that psychiatric diseases are closely related with neurodevelopmental abnormalities and this can be properly explained by apoptosis. It is known that Apo - 1/Fas is one of the genes in charge of apoptosis related with neurodevelopmental abnormalities. In this study, the association between bipolar disorder and functional polymorphism in Apo - 1/Fas promoter gene has been investigated.

Method : For 81 bipolar disorder patients and 217 healthy control subjects, Mval restriction fragment length polymorphism(RFLP) of Apo - 1/Fas promoter gene was analyzed after polymerase chain reaction(PCR) amplification.

Result : There was a statistical significant difference in genotypic distribution($\chi^2=16.656$, $df=2$, $p=0.0002$) and allelic frequencies($\chi^2=14.225$, $df=1$, $p=0.0002$) between bipolar disorder patients and healthy control subjects.

Conclusion : Our results suggest an association between functional polymorphism in Apo - 1/Fas promoter gene and bipolar disorder and provide the important genetic information related with the pathogenesis of the disease. Further studies employing larger samples are required to clarify the present results.

KEY WORDS : Apo - 1/Fas gene · Bipolar disorder.

서 론

가

(01 - PJ8 - PG6 - 01NE01 - 0003).

Kohwang Medical Research Institute, College of Medicine, Kyunghee University, Seoul, Korea

Seoul National Hospital, Seoul, Korea

†교신저자 : , 130 - 701 1
) (02) 961 - 0287,) (02) 958 - 0560 E - mail) jhchung@khu.ac.kr

가 33 (41%) 34.6 ± 8.7

1)

2) 217 가 105

가 (48.4%), 가 112 (51.6%) 41.8 ±

3) 4) 5) 11.5

2. 연구방법

1) DNA 분리

2ml
EDTA가 tube 24
DNA 가 - 20
DNA Isolation Kit(Roche, Mann-heim, Germany) 2ml
6ml 가 10
tube isopropranolol 650ul
가 (apoptosis) 8)9) 10 1.5ml tube
Apo - 1/Fas(CD95) 468ul 10
70% ethanol 900ul
DNA 10
Apo - 1/Fas(CD95) TE 200ul
promotor 가 10)11) 5 flanking (polymerase chain reaction, PCR)
가 12) - 20

2) DNA의 중합효소 연쇄반응(PCR)

Apo - 1/Fas(CD95) Apo - 1/Fas promotor
Apo - 1/Fas pro- (primer) Huang 13)
moter

방 법

1. 연구대상

2

DSM - (American Psychiatric Association, 1994)

81 가 48 (59%),

DNA PCR 100ng/ul DNA
1ul 2.5mM dNTP 1ul, 10pmol primer 1ul, Taq
polymerase(Neurotics, Daejeon, Korea) 0.2ul(1 unit),
10 PCR 3ul, 3 23.3ul 가
30ul Mas-
ter cycler gradient(Ependorf, Hamburg, Germany)

94 5 , denatura-
 tion 95 30 , annealing 58 60 , ex-
 tension 72 60 40
 extension 72 7

PCR DNA (332bp) ethidium bro-
 mide가 1.5% agarose gel
 UV transilluminator

3) 유전자형의 판별

PCR DNA 7ul Mval(Ro-
 che, Indianapolis, IN) 0.15ul, 2ul, 3
 10.85ul 가 20ul
 37 14 ethi-
 dium bromide가 3% agarose gel 100V
 UV transilluminator

(1). -670 A G
 3가

Mval 233/99bp
 (A/A homozygote), 188/99/45bp




Fig. 1. Genotype analysis of Mval RFLP in Apo-1/Fas promoter region. 1 : GG homozygous genotype ; 2 : AA homozygous genotype ; 3 : A/G heterozygous genotype.

(G/G homozygote), 233/188/99/45bp
 (G/A heterozygote)

3. 통계 분석

Fas/Apo -
 1 promoter
 Analysis System(SAS) Statistic
² - test
 p<0.05

결 과

1. Apo-1/Fas 유전자의 유전자형과 대립유전자 발현율 및 빈도

Fas/Apo - 1 promo-
 ter (genotype frequency)
 (allele frequency) 1
 Mval RFLP A/A
 31(38.3%), G/G 16(19.7%), G/A 34(42.0%)
 A 96(59.26%), G 66
 (40.74%)
 Mval RFLP
 A/A 36(16.6%), G/G 71(32.7%), G/A
 110(50.7%) , A 182
 (44.25%), G 252(55.75%)

2. 양극성 장애 환자군과 대조군 사이의 유전자형과 대립유전자의 발현율 및 빈도의 비교

(² = 16.66, df = 2, p = 0.0002)

Table 1. Allele frequencies and genotype distribution for Apo-1/Fas polymorphism in Korean bipolar patients and control subjects

	Genotypes(%)			Allele frequency(%)	
	A/A	G/G	A/G	A	G
Controls(n=226)	36(16.60%)	71(32.70%)	110(50.70%)	182(44.25%)	252(55.75%)
Patients(n=81)	31(38.27%)	16(19.75%)	34(41.98%)	96(59.26%)	66(40.74%)
² value	16.656			14.225	
df	2			1	
p value	0.0002*			0.0002*	
Odd ratio				2.014	
(95% CI)				(1.395 - 2.906)	

* : statistical significance at the level of p<0.05

($\chi^2=14.2254$, $df=1$, $p=0.0002$)
 가 . odd ratio G 가 .¹³⁾²⁴⁾
 A odd ratio가 가
 2 (OR=2.014 가 .
 [1.395 - 2.906]).

고 찰

(cell - mediated immunity)

²⁵⁾

Apo - 1/Fas(CD95) 가 .
 가 .
 Apo - 1/Fas promoter .
 가 .
 Apo - 1/Fas ,
 (Alzheimer 's dise- 가
 ase) (Down syndrome)
 Apo - 1/Fas 가 .
¹⁴⁾¹⁵⁾ , ,
 가 .

(neurodegenerative disease) .
 가 (neuro - plasticity)
¹⁶⁾¹⁷⁾ ,
 가 ,¹⁸⁾¹⁹⁾
 (Huntington 's disease) 81 217
 (neurodegeneration) gliosis Apo - 1/Fas promo-
²⁰⁾ ter Mval
 (cell loss) (atrophy) (neu- (restriction fragment length polymorphism, RFLP)
 roprotective/neurotrophic) .

결 론

Mval RFLP
 ($\chi^2=16.656$, $df=2$, $p=0.0002$)
 ($\chi^2=14.225$, $df=1$, $p=0.0002$)
 가 .
 Apo - 1/Fas promoter 가
 가
²¹⁾²²⁾
 , Apo - 1/Fas(CD95) tumor necrosis factor
 (TNF) , , ,
²³⁾ ,
 Apo - 1/Fas

중심 단어 : Apo - 1/Fas .

참고문헌

1. Benkelfat C. Serotonergic mechanism in psychiatric disorders: New research tools, new ideas. *Int Clin Psychopharmacol* 1993;8:53-56.
2. Yolken RH, Torrey EF. Viruses, Schizophrenia, and Bipolar Disorder. *Clin Microbiol Rev* 1995;8:131-145.
3. Winokur G, Tsuang M, Crowe R. The Iowa 500: affective disorder in relatives of manic and depressed patients. *Am J Psychiatry* 1982;139:209-212.
4. Bertelsen A, Harvald B, Hauge MA. Danish twin study of manic depressive disorders. *Br J Psychiatry* 1977;130:330-351.
5. Mendelwicz J, Rainerd JD. Adoption study supporting genetic transmission in manic depressive illness. *Nature* 1977;208:327-329.
6. Kringsen E. Genes and environment in mental illness. Perspectives and ideas for future research. *Acta Psychiatr Scand Suppl* 1993;370:79-84.
7. Nasrallah HA. Neurodevelopmental aspects of bipolar affective disorder. *Biol Psychiatry* 1991;29:1-2.
8. Post RM, Leverich GS, Xing G, Weiss RB. Developmental vulnerabilities to the onset and course of bipolar disorder. *Dev Psychopathol* 2001;13:581-598.
9. Kim SA, Kim Y, Choe BK, Lee HJ, Kim JW, Park JD, et al. Assessment of an Apo-1/Fas Promoter Polymorphism in Korean Schizophrenia Patients. *Korean J Physiol Pharmacol* 2002;6:161-163.
10. Cheng J, Liu C, Koopman WJ, Mountz JD. Characterization of human Fas gene. Exon/intron organization and promoter region. *J Immunol* 1995;154:239-245.
11. Rubert F, Visser E, Forbes L, Lindrige E, Wang Y, Watson J. Identification of a silencer, enhancer, and basal promoter region in the human CD95 (Fas/Apo-1) gene. *DNA Cell Biol* 1995;14:931-937.
12. Huang QR, Morris D, Manolis N. Identification and characterization of polymorphism in the promoter region of the human Apo-1/Fas (CD95) gene. *Mol Immunol* 1997;34:577-582.
13. Huang QR, Danis V, Lassere M, Edmonds J, Manolis N. Evaluation of new Apo-1/Fas promoter polymorphism in rheumatoid arthritis and systemic lupus erythematosus patients. *Rheumatology* 1999;38:645-651.
14. DeLaMonte SM, Sohn YK, Wands JR. Correlates of p53- and Fas (CD95)-mediated apoptosis in Alzheimer's disease. *J Neurol Sci* 1995;152:73-83.
15. Martinez M, Fernandez-Vivancos E, Frank A. Increased cerebrospinal fluid Fas (Apo-1) levels in Alzheimer's disease, Relation ship with IL-6 concentrations. *Brain Research* 2000;869:216-219.
16. Rajkowska G. Cell pathology in bipolar disorder. *Bipolar Disorders* 2002;4:105.
17. Manji HK, Moore GJ, Rajkowska G, Chen G. Neuroplasticity and cellular resilience in mood disorders. Millennium article. *Mol Psychiatry* 2000;5:578-693.
18. Rajkowska G, Halaris A, Selemon LD. Reductions in neuronal and glial density characterize the dorsolateral prefrontal cortex in bipolar disorder. *Biol Psychiatry* 2001;49:741-752.
19. Swayze VW II, Andreasen NC, Alliger RJ, Yuh WT, Ehrhardt JC. Subcortical and temporal structures in affective disorder and Schizophrenia: a magnetic resonance imaging study. *Biol Psychiatry* 1992;31:221-240.
20. Selemon LD, Rajkowska G, Goldman-Rakic PS. Abnormally high neuronal density in the schizophrenic cortex: a morphometric analysis of prefrontal area 9 and occipital area 17. *Arch Gen Psychiatry* 1995;52:805-818.
21. Chen RW, Chuang DM. Long term lithium treatment suppresses p53 and Bax expression. A prominent role in neuroprotection against excitotoxicity. *J Biol Chem* 1999;274:6039-6042.
22. Manji HK, Moore GJ, Chen G. Lithium up-regulates the cytoprotective protein Bcl-2 in the CNS in vivo: a role for neurotrophic and neuroprotective effects in manic depressive illness. *J Clin Psychiatry* 2000;6:82-96.
23. Bodmer JL, Burns K, Schneider P, Hofmann K, Steiner V, Thome M. TRAMP, a novel apoptosis-mediating receptor with sequence homology to tumor necrosis factor receptor 1 and Fas (Apo-1/CD 95). *Immunity* 1997;6:79-88.
24. Niino M, Kikuchi S, Fukazawa T, Miyagishi R, Yabe I, Tashiro K. An examination of the Apo-1/Fas promoter Mval polymorphism in Japanese patients with multiple sclerosis. *BMC Neurol* 2002;2:8.
25. Tsai SY, Chen KP, Yang YY, Chen CC, Lee JC, Singh VK, et al. Activation of indices of cell-mediated immunity in bipolar mania. *Biol Psychiatry* 1999;45:989-994.